---
schema_version: "secwatch.filing_event.v1"
accession: "0001099800-25-000003"
form_type: "8-K"
ticker: "EW"
cik: "0001099800"
company_name: "Edwards Lifesciences Corp"
filed_at: "2025-02-11T23:59:59+00:00"
generated_at: "2026-05-26T23:13:34.959228+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Edwards Q4 sales $1.39B (+9%), adjusted EPS $0.59; reiterates 2025 guidance

## Summary
- Q4 sales $1.39B (+9% YoY); TAVR $1.04B (+6%), TMTT $105M (+88%).
- GAAP EPS $0.58; adjusted EPS $0.59; full-year sales from continuing ops $5.5B.
- 2025 guidance reaffirmed: constant currency sales growth 8-10%, adjusted EPS $2.40-$2.50.
- Expect mid-year FDA approval for asymptomatic TAVR; presented EARLY TAVR and TRISCEND II trials.
- Cash $3.0B; debt $600M; adjusted gross margin 79.0%.

## SEC filing metadata
- accession: 0001099800-25-000003
- form_type: 8-K
- ticker: EW
- cik: 0001099800
- company_name: Edwards Lifesciences Corp
- filed_at: 2025-02-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1099800/000109980025000003/0001099800-25-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1099800/000109980025000003/ew-20250211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001099800-25-000003
- JSON: https://secwatch.observer/filing/0001099800-25-000003.json
- Plain text: https://secwatch.observer/filing/0001099800-25-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.